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Abstract
Background Natural ghrelin, a peptide growth hormone secretagogue, has a therapeutic potential in cachexia. We designed
a dose-finding trial of subcutaneous natural ghrelin to improve nutritional intake (NI) in advanced cancer patients.
Methods Advanced cancer patients with cachexia management (symptom management, physiotherapy, nutritional, and
psychosocial support) started with ghrelin at 32 μg/kg body weight, followed by 50% dose increases. Patients self-injected
ghrelin twice daily for 4 days followed by a wash-out period. After reaching the primary endpoint, maximal NI (minimal dose
for maximal NI), a maintenance period followed during which patients injected 10 doses of ghrelin per week. Safety parame-
ters, NI, and cachexia outcomes (symptoms, narratives, muscle mass, and strength) were measured over 6 weeks.
Results Ten patients with metastatic solid tumours were included, and six (100% male, mean age 61.8 ± 8.5 SD) received
ghrelin. Minimal dose for maximal NI was reached in four patients. Three patients reached the end-of study visit. Ghrelin
was well tolerated with variable results on appetite and eating-related symptoms but a positive effect in the narratives. Mean
Functional Assessment of Appetite & Cachexia Therapy score was 6.8 points lower at final measurement compared with base-
line, t(5) = 5.98, P < .01. Muscle mass was stable in two patients and increased in one patient, and muscle strength was stable
in three patients. Subjective tolerability was high. Patients showed a fluctuating trajectory, and median survival was 88 days
(51–412 days).
Conclusions Ghrelin was safe in advanced patients with cancer cachexia without dose-limiting toxicity and well tolerated.
The intervention was very complex, and the number of patients included was small. There was a positive effect on nutritional
intake and patient narratives.
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Background
Cancer cachexia remains a frequent problem in advanced
cancer patients and their families.1 It ranges from 24% of ad-
vanced cancer patients at the time of diagnosis to >80% at
the terminal stages.2 Cancer cachexia is clinically relevant be-
cause it is related to poor performance status, poor tolerance
of anti-neoplastic treatments,3 increased pulmonary infec-
tions, symptoms such as fatigue/asthenia,4 anorexia, early sa-
tiety, chronic nausea, shortness of breath, sleep/wake
disturbances, malaise, altered body image, family distress,5
and ultimately, unnecessary suffering6 and shorter survival.7
Key components of cachexia are integrated into clinical
classification and assessment: (i) anorexia/reduced food
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intake, (ii) catabolic drive (caused by inflammation and tu-
mour activity), (iii) decreased muscle mass and strength,
and (iv) impact of cachexia (psychosocial and physical
functioning).8 Current treatments of cancer cachexia include
both standard management and pharmacological and
nutritional interventions. Standard palliative cancer care
provides treatment of the so-called secondary reasons for
cachexia and loss of appetite/decrease nutritional intake,
such as stomatitis, dysphagia, uncontrolled symptoms, and
constipation.9
A basic nutritional counselling programme should be in
place to treat dietary problems and support conscious control
of eating. Nutritional interventions for cancer-related ca-
chexia, including enteral and parenteral nutrition and nutri-
tional counselling, have limited effect on only a minority of
patients and isolated positive outcomes. Physical activity
counselling should encourage patients to make minimal phys-
ical stimuli to their muscles. Because emotional and social as-
pects can affect food intake, psycho-social support should be
in place in order to relieve eating related distress of patients
and family members. As pharmacological treatments, cur-
rently only progestin (effect on appetite, body weight, mainly
water, and thromboembolic complications), corticosteroids
(short-term effect of less than a few weeks, then insulin resis-
tance, muscle wasting and increased risk for infections), and
prokinetic agents (mainly for patients with early satiety) are
available.10
Ghrelin, a 28 amino acid peptide discovered in 1999, is
an endogenous ligand for the growth hormone
secretagogue receptor, displaying dose-dependent growth
hormone-releasing activity.11 Ghrelin is predominantly se-
creted by gastric endocrine cells. When administered periph-
erally, it stimulates growth hormone secretion and food
intake, triggers a positive energy balance, and produces
weight gain through a central mechanism involving hypotha-
lamic neuropeptides. Ghrelin increases during periods of
fasting or under conditions associated with negative energy
balance such as starvation or anorexia. In contrast, ghrelin
levels are low after eating, or with hyperglycaemia, and in
obesity.
Ghrelin has had stimulatory effects on appetite and
food intake, lean body mass, gastrointestinal motility, and
energy metabolism, and it has alleviated cancer
chemotherapy-associated dyspepsia.4,12,13 Ghrelin has a pos-
sible effect on skeletal muscle mitochondrial function, inflam-
matory changes, and insulin signalling.14
In one pilot study, seven cancer patients had 31% higher
energy intake with intravenous ghrelin than with placebo
(5 pmol/kg/min for 180 min) with no adverse effects.13 A trial
on intravenous ghrelin reports good tolerability and safety of
single intravenous application of 2 and 8 μg/kg ghrelin i.v.15
The aim of this trial is to investigate the effect of individu-
ally dose-optimized (dose escalation) twice-daily subcutane-
ous (s.c.) natural ghrelin on safety, toxicity, tolerability,
nutritional intake, anorexia, eating-related symptoms, muscle




Adult patients were recruited in the outpatient and inpatient
services of the Oncology Department at the Cantonal Hospital
St. Gallen, Switzerland, specifically from specialized cancer ca-
chexia clinics.
Patients with any type of advanced incurable solid tumour
and cancer cachexia were assessed for eligibility. The tumour
situation had to be expected to remain stable without rapid
progression in the next weeks. Anti-neoplastic treatment
was allowed if it was given continuously, defined as weekly,
or biweekly, and if the treatment did not cause more than
Grade 1 adverse event (AE) of decreased oral intake and gas-
trointestinal dysfunction.
Cancer cachexia was defined as the involuntary loss of
weight of 2% of total body weight in 2 months or 5% in
6 months and was ongoing in recent weeks. Patients had to
be able to eat, defined as no severe structural barriers in
the upper gastrointestinal tract and no bowel obstruction. Pa-
tients were not allowed to have corticosteroids except for
maximum of 2 days for chemotherapy, no progestin therapy
within the last 2 weeks, and no anabolic drugs within the last
month. Prokinetic medications were allowed, if given in a
fixed dose for 2 weeks before study start, and expected to
be continued during the trial period.
Laboratory test results must have been within these
ranges: absolute neutrophil count ≥1.5 × 109/L, platelet count
≥100 × 109/L, serum creatinine ≤2.0 mg/dL, total bilirubin
≤1.5mg/dL, and aspartate aminotransferase and alanine ami-
notransferase ≤2 × upper limit of normal or ≤5 × upper limit
of normal if hepatic metastases are present.
Presence of a normal level of consciousness with a mini
mental status of ≥25/30 points was required, and the patient
had to give informed consent.
Intervention
After basic cachexia management, the study was divided into
a titration period and a maintenance period.
Basic cachexia management
Patients were instructed about individual regular physical
activity by a physical therapist and received basic psychoso-
cial/spiritual assessment and treatment. Patients had at least
one nutritional counselling session by a specialized nutrition-
ist for optimization of nutritional intake (multiple small meals,
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food preference, etc.) and for the instruction of recording nu-
tritional intake.
Ghrelin was applied by the research staff at the clinic.
During the maintenance period, home application was per-
formed. Ghrelin applied at patients’ homes was handed out
as vials containing powdered ghrelin. The patient stored the
vials for a maximum of 1 week in a special box in the freezer.
The starting dose was 32 μg/kg body weight, which has
been shown to be safe in human beings. After the first three
patients, the starting dose level was increased to Level 2. In
the first four dose levels, the dose was increased by 50%.
From the fifth dose level onwards, the increase was 25%:
• Dose level 1 = 32 μg/kg
• Dose level 2 = 48 μg/kg
• Dose level 3 = 72 μg/kg
• Dose level 4 = 108 μg/kg
• Dose level 5 = 135 μg/kg
• Dose level 6 = 169 μg/kg
• Dose level 7 = 211 μg/kg
The maximum tolerable dose was set as 20 mg ghrelin
(equivalent to 5 mL) due to the high drug volume to be ad-
ministered s.c.. Volumes of >2.5 mL had to be divided into
two syringes, that is, the subject had to be injected twice.
The first dose of each dose level was always administered in
the clinic for safety reasons.
Titration period in hospital
During the titration period, treatment was conducted with
twice daily s.c. ghrelin injection for 2 days.
Maintenance period in hospital and at home
All patients who reached the maintenance period injected
ghrelin twice daily on 21 days (on five out of seven days per
week, i.e. Monday to Friday).
Outcomes
Nutritional intake
Nutritional intake was measured according to best practice
adapted to the individual patient. This was performed using
a food diary, photographs, and the use of a digital scale to
weigh meals. In addition, the nutritionist called the patients
once per day to remind him/her to complete the food diary.
The nutritionists estimated the caloric equivalent of food
eaten.
Definition of minimal dose for maximal nutritional intake
For each individual patient, data were reviewed to establish
the lowest ghrelin drug level associated with the maximum ca-
loric nutritional intake in a 24 h period [minimal dose for
maximal nutritional intake (MD-MANI)]. A substantial increase
in intake was defined as at least 10%more caloric intake com-
pared with the baseline. Doses were escalated as long as a sub-
stantial increase in intake was measured and no toxicity
occurred. MD-MANI was determined when no significant in-
crease was measured anymore or toxicity occurred. At this
point, patients were referred to the maintenance period.
Toxicity and tolerability
The maximal ghrelin dose level was deemed to be one at
which there was no Grade 3/4 AE or serious AE (SAE) likely as-
sociated with the investigational product. Common toxicity
criteria from the time of first drug administration until study
termination and 30 days follow-up were applied. The assess-
ment of any grade AE and SAE included neuropsychologic
side effects (like, e.g. dizziness) and injection site reactions
and haematological/biochemical alterations. Assessments
were performed according to good clinical practice (GCP).
Anorexia eating-related symptoms, narratives
Anorexia assessment was performed using the Edmonton
Symptom Assessment Scale.16 Eating-related symptoms like
appetite, satiety, nausea, abdominal discomfort, and dyspep-
sia were assessed by the modified German Functional Assess-
ment of Appetite & Cachexia Therapy (FAACT+), which includes
15 items in a 4-point categorical scale. FAACT+ is an adapted
and translated version of the FAACT questionnaire.17 Addition-
ally, narratives from patients and proxies were collected.
Muscle mass and muscle strength (muscularity)
Muscle mass was measured by abdominal computerized to-
mography scan. Images were analysed using Slice-O-matic
software V4.3 (Tomovision) using pre-established thresholds
of Hounsfield unit.18,19
At each time point, hand grip strength was measured six
times. Compliance of the patient was estimated in order to
get reliable test results. The mean value out of all six measures
of each hand was calculated. (JAMAR® Hand Dynamometer).20
Physical function
A validated activity monitor the ActivPAL (PALTechnologies
Ltd, Glasgow, Scotland), based on a uni-axial accelerometer
was used.21 It identifies episodes of walking, sitting, and
standing, allowing the measurement of both activity and inac-
tivity. Furthermore, it records the number of steps and in-
stantaneous cadence. Each time span of measurement was
3 days.
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Statistical analyses
All patients were included in the analyses. Descriptive
analysis was performed. Paired t tests were conducted on
pre–post ghrelin measurements. The level of statistical signif-
icance was set at P < .05.
Ethical considerations
The study protocol was written and the trial was performed
in accordance with the Declaration of Helsinki, the Guidelines
of Good Clinical Practice issued by the International Council
for Harmonisation of Technical Requirements for Pharmaceu-
ticals for Human Use and Swiss regulatory authority’s
requirements.
The Study was approved by the local ethics committee
(EKSG SG 294/08).
Results
Over a 1 year period, patients in the cachexia clinics were
screened for trial participation. The CONSORT-diagram is
displayed in Figure 1.
Ten patients were included in the study, but only six pa-
tients received the investigational product. The remaining
four patients never got the drug due to rapid progression of
the cancer disease.
Age ranged from 48 to 76 years. The tumour types repre-
sented were pancreatic, head and neck, lung, and gastroin-
testinal cancer. Average weight loss in the last 6 months
was 15 kg.
An overview on patient demographics is given in Table 1,
and MD-MANI is presented in Table 2. In the following para-
graphs, patients receiving Ghrelin are described case by case:
Patient 1
A 61-year-old male patient with pancreatic cancer, which had
metastasized to the liver, presented with a weight of 75 kg
and body mass index (BMI) of 25.4. In the previous six
months, he had lost 17 kg, 15 kg of which had been lost in
the previous two months. He received Gemcitabine. He had
a Karnofsky score of 80 and an Eastern Cooperative Oncology
Group (ECOG) score of 1. This patient reached MD-MANI at
Dose Level 2 with a 14% increase in kilocalorie intake com-
pared with baseline. Patient 1 commented about his experi-
ence using ghrelin saying, ‘I don’t leave home without a
snack’ and ‘I have to eat every two to three hours.’
FIGURE 1 CONSORT flow diagram.
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Comparing pre-study measurements with post-study mea-
surements, he exhibited no change in muscle mass, a 2% in-
crease in muscle strength, and a 7% decrease in steps per
day. This patient survived 412 days.
Patient 2
A 66-year-old male patient with pancreatic cancer, which had
metastasized to the lymph nodes, presented with a weight of
52 kg and a BMI of 17.9. He had lost nine kg in the previous
six months, including 0.4 kg of weight gain in the previous
two months. He received Gemcitabine. He had a Karnofsky
score of 70 and an ECOG core of 2. MD-MANI could not be
established for this patient. At all ghrelin dose levels, kilocal-
orie intake was lower than baseline, with the exception of
Dose Level 2, when there was a 2% increase in kilocalorie in-
take. This small increase did not meet the pre-set definition
of MD-MANI being at least 10% increase in kilocalorie com-
pared to baseline. Patient 2 experienced an SAE, an episode
of hypothermia, which was deemed attributable to the
ghrelin application. Nonetheless, this patient reported posi-
tive impressions of taking ghrelin, stating that ‘I feel fresher
and I eat more.’ Over the course of the study, he exhibited
a 5% decrease in muscle mass. Post-study measurements of
muscle strength steps per day were not available. This pa-
tient survived 53 days.
Patient 3
A 76-year-old male patient with gastrointestinal cancer,
which had metastasized to the liver, presented with a weight
of 48 kg and a BMI of 16.0. In the previous 6 months, he had
lost 14 kg, 13 of which had been lost in the previous
2 months. He received Capecitabine. He had a Karnofsky
score of 60 and an ECOG score of 2. This patient reached
MD-MANI at Dose Level 4, when there was an 18% increase
in kilocalorie intake compared with baseline. Patient 3 made
the following comment about using ghrelin: ‘Feel more ac-
tive.’ During the study period, Patient 3 was hospitalized for
atrial fibrillation, which was an SAE deemed unrelated to
ghrelin. This patient survived 51 days.
Patient 5
A 63-year-old male patient with advanced mesothelioma pre-
sented with a weight of 70 kg and a BMI of 22.6. Data regard-
ing weight loss in the previous 6 months were not available..
He received FOLFIRI. He had a Karnofsky score of 60 and an
ECOG score of 1. This patient reached MD-MANI at Dose
Level 3 with a 29% increase in kilocalorie intake compared
with baseline. Patient 5’s opinion about using ghrelin was
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well-being.’ Patient 5 experienced an increase in tumour pain,
an SAE deemed unrelated to ghrelin. Comparing pre-study
measurements with post-study measurement, he exhibited
a 3% decrease in muscle mass. Post-study measurements
for muscle strength, steps per day could not be obtained. This
patient survived 62 days.
Patient 9
A 48-year-old male patient with head and neck cancer, which
had metastasized to the lungs, liver, and lymph nodes, pre-
sented with weight of 35 kg and a BMI of 15.8. He had lost
17 kg in the previous 6 months, of which 11 kg had occurred
in the previous 2 months. He did not receive chemotherapy.
He had a Karnofsky score of 80 and an ECOG score of 1. This
patient reached MD-MANI at Dose Level 3, at which point the
patient took in 11% more kilocalorie compared with baseline.
A secondary malignancy was diagnosed in Patient 9, an SAE
deemed unrelated to ghrelin. Comparing pre-study measure-
ments with post-study measurements, he exhibited a 9% de-
crease in muscle mass, a 6% increase in muscle strength, and
a 19% decrease in steps per day. This patient survived
114 days.
Patient 10
A 57-year-old male patient with head and neck cancer, which
had metastasized to the lungs, presented with a weight of
59 kg and a BMI of 18.6. He had lost 19 kg in the previous
6 months, including 3 kg of weight gain in the previous
2 months. He received Cetuximab. He had a Karnofsky score
of 90 and an ECOG score of 1. This patient reached
MD-MANI at Dose Level 3 when kilocalorie intake increased
11% compared with baseline. Patient 10 commented that
on ghrelin, ‘my stomach growls’. Comparing pre-study mea-
surements with post-study measurements, he exhibited no
change in muscle mass, a 6% increase in muscle strength,
and a 16% increase in steps per day. This patient survived
166 days.
Anorexia and eating-related symptoms
Anorexia, as measured on a visual analogue scale, showed
fluctuation during the study as shown in Figure 2. FAACT
sum scores trajectories are displayed in Table 3. A paired t
test showed that mean FAACT scores were 6.8 points lower,
significantly lower at the final measurement as compared
with the first measurement, t(5) = 4.88, P = 0.005. A paired
t test of the first and last visual analogue scale measurements
showed no statistically significant change, t(5) = 0.47,
P = 0.67.
Table 2 Nutritional intake with MD-MANI in bold
Patient 1 Dose level 1 2 3 4 2 2 2
Kcal 2350 2691 2415 2627 2650 2005 2581
Increase BL (%) 0 +14 +3 +12 +12 15% 10
Patient2 Dose level 1 2 3 4 5 0 0
Kcal 934 1,394 1,345 999 752 971 1047
Increase BL (%) 31.50 2 1 26.8 44 28 23
Patient3 Dose level 1 2 3 4 5 4 0
Kcal 1061 1189 1285 1331 1275 337 246
Increase BL (%) 6 +6 +14 +18 +13 70 78
Patient 5 Dose level 2 3 4* 5 3 3 3
Kcal 1580 1908 1585 1553 1220 1554 1843
Increase BL (%) +7 +29 +7 +5 18 +5 +25
Patient 9 Dose level 2 3 4 5 3 3 3
Kcal 3035 3544 3044 3194 3404 3125 2559
Increase BL (%) 5 +11 5 0 +6 35 20
Patient 10 Dose level 2 3 4 3 3 3
Kcal 1900 2029 2027 1913 1863 2322
Increase BL (%) +3 +11 +10 +4 +1 +26
Due to S-NIS trial, chair decided to rise one level.
BL, baseline; MD-MANI, minimal dose for maximal nutritional intake.
FIGURE 2 Appetite. Appetite VAS (1–10, 0 best, 10 worst).
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Muscle mass and strength, physical activity
Muscle mass was stable in two patients and increased in one
patient, and muscle strength was stable in three patients. The
full results can be seen in Table 4.
The change in steps walked was also highly variable, de-
pending on the patient. The change in step count from first
measurement to last measurement ranged from 92% to
100%. The difficulties of measuring physical activity among
a palliative cohort were apparent. For example, Patient 5
was non-compliant when it came to using the ActivPAL de-
vice, due to his perception that the device was inconvenient.
Results are displayed in Table 5.
The injections were well tolerated at the injection site, and
subjective tolerability was high. Patients showed a fluctuation
trajectory, and survival was short: median survival was
88 days (min 51 days; max 412 days).
The appendix provides additional data about concomitant
medications, vital signs at baseline, C-reactive protien levels,
and adverse events.
Discussion
All six patients who received s.c. ghrelin in the study suffered
from far advanced cancer and experienced major weight loss.
Five of the six patients were under anticancer treatment. All
of them were male. Ghrelin was well tolerated and was per-
ceived positively by individual study participants. There was
a positive effect on nutritional intake, and MD-MANI could
be determined in four out of six patients. There seemed to
be an effect with titration but without linearity. Overall, a
definite dose for maximal nutritional intake could not be de-
cided due to the variability of patient outcomes and the small
sample size.
The two best responders went into a compassionate use
programme because they did not want to abstain from the
drug. This was approved by the ethics committee. There
was a change in appetite, and according to patient narratives,
Table 3 Functional Assessment of Appetite & Cachexia Therapy (FAACT)
FAACT 0 FAACT 1 FAACT 2 FAACT3 FAACT 4 FAACT 5 FAACT 6 FAACT 7
Patient 1 33 31 31 32 33 33 30 30
Patient 2 38 28 27 27 31 33 N/A N/A
Patient 3 34 30 33 27 24 26 N/A N/A
Patient 5 35 35 34 33 34 35 35 22
Patient 9 38 41 41 37 40 37 40 32
Patient 10 38 33 31 30 31 35 32 N/A
FAACT (lower scores better).
N/A, not available.
Table 4 Muscle mass and strength
Muscle mass TAG (cm3) Muscle strength (kg)
Before After % change Before After % change
Patient 1 115 115 0% 28.4 28.9 2%
Patient 2 95 90 5% 17.8 ND N/A
Patient 5 155 150 3% 12.0 ND N/A
Patient 8 115 125 9% 44.6 43.7 2%
Patient 9 120 109 9% 35.0 37 6%
Patient 10 115 115 0% 34.0 36 6%
N/A, not available; ND, no data.
Table 5 Daily step counts













1 14/12/09 2056 7%
2 23/06/09 2210
2 24/06/09 2828
2 25/06/09 4418 100%
3 10/08/09 6764
3 01/09/09 532 92%
5 — — —
9 25/03/10 2886 —
9 26/03/10 3852 —
9 27/03/10 5884 —
9 28/03/10 3836 —
9 29/03/10 1302 —
9 16/04/10 6662 —
9 17/04/10 10 812 —
9 18/04/10 3936 —
9 19/04/10 202 —
9 07/05/09 3234 —
9 08/05/09 6940 —
9 09/05/09 2342 19%
10 20/07/10 5400 —
10 21/07/10 6748 —
10 22/07/10 3228 —
10 23/07/10 3650 —
10 24/07/10 2340 —
10 27/08/10 7718 —
10 28/08/10 6896 —
10 29/08/10 2740 —
10 30/08/10 13 622 —
10 31/08/10 860 —
10 01/09/10 6290 16%
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eating experience and eating-related symptoms also
improved.
During the trial, four SAEs occurred. A clinical relevant hy-
pothermia was considered to be related to the investigational
product.22 The other events were considered as not drug re-
lated. An occurrence of a secondary malignancy was seen;
this was considered as not unusual in a patient heavily
pre-treated with several cytotoxic agents.
Muscle mass and muscle strength measures yielded vari-
able results, and ActivPAL measurement encountered techni-
cal challenges with extreme fluctuations in activity between
days. More measurements and longer measurement times
could have improved the chances of drawing meaningful con-
clusions. A positive effect on muscle mass is difficult to mea-
sure in an advanced cancer population because the natural
course of muscle loss is difficult to predict. Additionally,
symptoms perception and subjective narrative response is in-
fluenced by several factors, such as motivation, stimulation
by proxies, and rapport with the treatment team.
In recent years, several trials have been conducted with
substances similar to ghrelin. Anamorelin, a synthetic growth
hormone secretagogue receptor agonist, has been investi-
gated in chemotherapy trials to increase lean body mass
and improve muscle strength. Anamorelin improved muscle
mass but not the functional co-primary functional outcome,
handgrip strength.23,24 The Food and Drug Administration
and the European Medicines Agency declined approval, but
ghrelin and analogue substances remain an interesting topic
in cachexia research.
The strength of the present case series is the innovative
design and the measurement of state-of-the-art outcomes
in cachexia research. A major weakness is the low number
of patients included. Conducting the study was very labori-
ous, and it was challenging to find stable phases in dynamic
trajectories near end of life. Because there was no compara-
tor, the study is prone to placebo effects.
Patients with advanced cancer experienced unexpected tu-
mour progression and presented with heavily fluctuating
symptoms, which affected nutritional intake. To reflect the
proposed effect of ghrelin on appetite, food intake, muscle,
inflammation, and psychological measurements, a multitude
of outcomes representing different domains of cancer ca-
chexia were measured, because meaningful outcomes in can-
cer cachexia research remain a matter of debate.25 These
target outcomes may change along the trajectory of cancer
cachexia.26 In the early stage of cachexia, muscle mass and
function are the central focus. An effective drug could even
prevent the development or progression of cachexia. This is
in contrast to the end stage of cachexia, when symptom con-
trol and palliation become priorities. In this series, Ghrelin
was applied mainly near the end of life, but further study of
Ghrelin is compelling because it is one of the few substances
that could potentially have a positive effect along the whole
cachexia trajectory.
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Appendix A.
Table A1 Concomitant medication










1 Gemcitabine Cytotoxic agent
1 Mephamesone Steroid
2 Erythrocyte concentrate Blood
2 Mephamesone Steroid
2 Gemcitabine Cytotoxic agent




5 Macroolum B350 Laxans
5 Metoclopramide Prokinetic
5 Cisplatin Cytotoxic agent
5 Carboplatin Cytotoxic agent
5 Pemetrexed Cytotoxic agent
9 Dalteparin Heparin
9 Cetuximab EGFR inhibitor
10 Mistletoe Complementary
EGFR, estimated glomerular filtration rate.














1 103 75 84 36.4
2 92 55 71 36.6
3 106 69 79 36.0
5 139 85 80 —
9 125 80 104 36.2
10 107 69 72 36.8
Table A3 C-reactive protein
Patient number Measurement event CRP (mg/L)
1 Baseline 12
1 Titration 1 38
1 Titration 2 8
1 Titration 3 23
1 Titration 4 11
1 Maintenance 1 8
1 Maintenance 2 54
1 Maintenance 3 12
1 Conclusion 18
2 Baseline 120
2 Titration 1 221
2 Titration 2 226
2 Titration 3 187
2 Titration 4 157




3 Titration 1 186
3 Titration 2 119
3 Titration 3 133
3 Titration 4 146
3 Maintenance 1 98
5 Baseline 169
5 Titration 1 150
5 Titration 2 132
5 Titration 3 122
5 Titration 4 134
5 Maintenance 1 134
5 Maintenance 2 125
5 Maintenance 3 113
5 Conclusion 104
9 Baseline 13
9 Titration 1 10
9 Titration 2 23
9 Titration 3 14
9 Titration 4 6
9 Maintenance 1 18
9 Maintenance 2 23
9 Maintenance 3 43
9 Conclusion 61
10 Baseline 9
10 Titration 1 8
10 Titration 2 11
10 Titration 3 19
10 Maintenance 1 17
10 Maintenance 2 9
10 Maintenance 3 110
10 Conclusion 18
10 D. Blum et al.


































































































































































































































































































































































































































































































































































































































































































































































































































































Individually dose-optimized (dose escalation) subcutaneous 11
Journal of Cachexia, Sarcopenia and Muscle 2021
DOI: 10.1002/jcsm.12659
